Ben brings both biopharma expertise and diverse experience. For the past five and a half years, he was a senior manager in PwC’s Health Research Institute. He developed reports on various policy issues and business trends, particularly in the pharma and medtech sectors, provided research for clients and spoke at industry events. Previously, he was a journalist with Pharmaceutical Executive; Medical Marketing & Media, PRWeek and Direct Marketing News; and Ad-Fax Media. During his college days, he taught English in China.
He lives in Orlando, Fla. Outside of work, Ben enjoys playing guitar, welcomes your recommendations for great novels and avidly pursues hiking, biking and other outdoor activities.
Latest From Ben Comer
From pre-med to pharma lab rat to deputy director of operations at the FDA, Khushboo Sharma, a 2021 In Vivo Rising Leader and current VP of science and regulatory affairs at BIO, has spent her career pursuing a goal she says the FDA and biopharma industry have in common: ensuring that innovative drugs get to patients.
Aside from a few high-profile exceptions, the biopharma industry supply chain has remained secure and resilient during the COVID-19 pandemic, outperforming retail and consumer goods. Chip Davis, Jr., head of the Healthcare Distribution Alliance, spoke with In Vivo about the need for a long-term industrial policy for drug manufacturing, real-time data-sharing and transparency in the supply chain, and minimizing disruptions.
Through an ever-growing number of partnerships, grants and investments in the health care sector, Microsoft is taking a lead from behind approach to improve and expand interoperability, increase data security and analytics, and provide partners with tools, technology, and a platform for growth.
US Congressional Democrats made Halloween the new deadline for President Biden’s Build Back Better Act, to be passed through the reconciliation process. Savings generated from prescription drug price cuts represent a key pot of money to offset the legislation’s other spending initiatives.
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
If targeted therapies for cancer represent a more precise, laser-like attack on solid tumors and blood cancers, cytotoxic chemotherapies are more like a ham-fisted boxer punching every cell in sight. New methods for delivering chemotherapy directly into cancer cells may help to improve efficacy and reduce – or eliminate – damaging and sometimes deadly side effects.